The company leaves the door open for Trodelvy pre-chemo, despite Ascent-07’s failure.
ApexOnco Front Page
Recent articles
Giredestrant’s adjuvant benefit looks similar to that of Kisqali and Verzenio.
Of 15 treatment-emergent adverse events, only one was deemed related to therapy.
The company will try to get the Komzifti QTc prolongation warning removed.
On efficacy, at least, BeOne’s BTK degrader shows an edge.
The first stage of Preserve-003 shows a survival benefit in post-PD-(L)1 lung cancer – with caveats.
It’s less about being fast, more about producing a better product.
Cross-licensing pact brings in SKB105, and hands off China rights to CR-001 before first-in-human studies.
